Proteus syndrome synonyms

Proteus syndrome is a rare, complex, and highly variable overgrowth disorder that does not have widely used alternative names, though it is occasionally historically referred to as "Wiedemann syndrome" or "partial gigantism." Because it is a distinct clinical entity caused by a somatic activating mutation in the AKT1 gene, medical professionals exclusively use the term Proteus syndrome to ensure diagnostic accuracy and clarity in clinical documentation.

Why does Proteus syndrome have multiple names?

The name Proteus syndrome was coined in 1983 by Dr. Michael Cohen and Dr. Hans-Rudolf Wiedemann. They named the condition after the Greek sea god Proteus, who could change his shape, to reflect the highly variable, mosaic, and unpredictable nature of the overgrowth seen in patients. In older medical literature, you may encounter the term "Wiedemann syndrome," though this is now considered imprecise. Because Proteus syndrome is a specific genetic condition, avoid confusing it with other overgrowth syndromes like Klippel-Trénaunay syndrome or CLOVES syndrome, which were once sometimes misdiagnosed under the Proteus syndrome umbrella before the discovery of the AKT1 gene mutation.

How is Proteus syndrome classified in medical systems?

Standardized medical classification systems use specific codes to ensure consistency in research and insurance billing. When searching for information, you will find Proteus syndrome categorized under the following official identifiers:

• OMIM (Online Mendelian Inheritance in Man): #176920


• Orphanet: ORPHA745


• ICD-10: Q87.3 (Congenital malformation syndromes involving overgrowth)


• ICD-11: LD24.5 (Proteus syndrome)

What terminology should patients and providers use?

For the sake of medical clarity, Proteus syndrome is the only term currently recognized by the international medical community, including the NIH and the Proteus Syndrome Foundation. Using the official name is critical because it helps clinicians distinguish this condition from other PIK3CA-related overgrowth spectrum (PROS) disorders. Within our DiseaseMaps community, 5 individuals have identified with this diagnosis, and using the standard, globally recognized name ensures that these community members can access the most relevant research, clinical trial information, and support resources available.

Is the name of the condition changing?

The nomenclature has stabilized significantly since the 2011 discovery of the somatic AKT1 c.49G>A mutation, which confirmed Proteus syndrome as a unique clinical entity. While the condition was historically confused with other segmental overgrowth disorders, modern genetic testing has allowed for precise diagnosis. You should not expect any major name changes in the near future, as the current term is deeply embedded in the genetic and clinical literature.

Next steps

• Consult a clinical geneticist to confirm a diagnosis via targeted molecular testing for the AKT1 mutation.


• Review your medical records to ensure "Proteus syndrome" is listed, rather than vague descriptors like "unilateral overgrowth."


• Connect with the Proteus Syndrome Foundation to access specialized care networks and patient registries.


• Join the DiseaseMaps.org community to share experiences and find peer support with other families navigating this diagnosis.

Medical disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always consult with a qualified healthcare provider regarding your specific medical condition.

References

• NIH GARD (Genetic and Rare Diseases Information Center): Proteus Syndrome Overview


• Orphanet: Proteus Syndrome Information Portal


• OMIM: Proteus Syndrome (#176920)


• Proteus Syndrome Foundation: Official Patient Advocacy Resources